# MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Canonical URL: https://biopharmsignal.com/news/MDWD/mediwound-to-present-at-the-h-c-wainwright-28th-annual-global-investment-confere-f4c810ab
Ticker: MDWD
Company: MediWound
Source: MediWound
Published: 2026-09-02 11:00 EST
## Summary

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a...

## Article Body
MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference

YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

The fireside chat, moderated by Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwright, is scheduled for Monday, September 14, 2026, at 2:00 p.m. ET.

A live webcast of the fireside chat will be available here and on MediWound’s website under the Events & Presentations page in the Investors section.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid ® , is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx ® , is an investigational therapy for the debridement of chronic wounds, with the potential to become, if approved, a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter) .

| MediWound Contacts: |  |  |  |
| --- | --- | --- | --- |
| Hani Luxenburg Chief Financial Officer MediWound Ltd. ir@mediwound.com |  | Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com |  |
## Recent Company News
- 2026-09-02 11:00 EST — [MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/MDWD/mediwound-to-present-at-the-h-c-wainwright-28th-annual-global-investment-confere-f4c810ab) — Source: MediWound
- 2026-08-13 11:00 EST — [MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/MDWD/mediwound-reports-second-quarter-2026-financial-results-and-provides-corporate-u-5b3d2b7e) — Source: MediWound
- 2026-07-29 12:00 EST — [MediWound to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MDWD/mediwound-to-report-second-quarter-2026-financial-results-11b5e0a5) — Source: MediWound
- 2026-05-27 11:00 EST — [MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/MDWD/mediwound-reports-first-quarter-2026-financial-results-and-provides-corporate-up-d4323a9b) — Source: MediWound
- 2026-05-07 12:00 EST — [MediWound to Report First Quarter 2026 Financial Results](https://biopharmsignal.com/news/MDWD/mediwound-to-report-first-quarter-2026-financial-results-6c090220) — Source: MediWound
## Related News
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)
- 2026-09-04 20:05 EST — NTLA — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-250d5dd9)